Observing the same favorable biodistribution (NCT04040686) would make the tracer a promising noninvasive tool to discriminate HER2 status in metastatic (breast) cancer, independent of ongoing HER2-targeted antibody treatment. This evidence concerns the gene ERBB2 and breast cancer.